Duration of action of a chimeric interleukin-2 receptor monoclonal antibody, basiliximab, in pediatric kidney transplant recipients
Ghislaine Sterkers(Délégation Paris 7), Chantal Loirat(Assistance Publique – Hôpitaux de Paris), Hélène Ansart‐Pirenne(Hôpital Robert-Debré), Anne Maisin(Hôpital Robert-Debré), Véronique Baudouin(Assistance Publique – Hôpitaux de Paris), Pierre Cochat(Société Nationale des Chemins de Fer Français (France)), Patrick Niaudet(Hôpital Necker-Enfants Malades)
Cited by 22
Related Papers
Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1
|New England Journal of Medicine|2021|509
The ciliary gene RPGRIP1L is mutated in cerebello-oculo-renal syndrome (Joubert syndrome type B) and Meckel syndrome
|Nature Genetics|2007|495
Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy
|Kidney International|2011|361
Primary hyperoxaluria Type 1: indications for screening and guidance for diagnosis and treatment
|Nephrology Dialysis Transplantation|2012|335
Clinical Features of Anti-Factor H Autoantibody–Associated Hemolytic Uremic Syndrome
|Journal of the American Society of Nephrology|2010|296